Journal Mobile Options
Table of Contents
Vol. 71, No. 2, 2011
Issue release date: March 2011
Gynecol Obstet Invest 2011;71:136–140
(DOI:10.1159/000316049)

Quantitative Detection of Serum Survivin and Its Relationship with Prognostic Factors in Ovarian Cancer

No J.H. · Jeon Y.-T. · Kim Y.-B. · Song Y.-S.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: This study was conducted to determine the clinical significance of serum survivin in ovarian cancer. Methods: A total of 65 patients with ovarian tumors including 21 epithelial ovarian cancer, 22 benign epithelial ovarian tumor, 13 dermoid cyst and 9 endometrioma cases were investigated. All histologic types of cancer were serous carcinoma except for 1 case of undifferentiated carcinoma. ELISA was employed to evaluate the serum survivin levels. For statistical analysis, we used Fisher’s exact test, Spearman’s correlation coefficient test, the Mann-Whitney U test, the log-rank test and Cox regression analysis. Results: The survivin level was higher in serous ovarian cancer than in benign epithelial tumors with marginal significance. In ovarian cancer, serum survivin was positively correlated with age, advanced stage and poor disease-free survival. Interestingly, high survivin level positivity was associated with positive peritoneal cytology and omental metastasis of ovarian cancer. Conclusions: Our data collectively suggest that serum survivin reflects the peritoneal metastasis of serous ovarian cancer and may thus be useful as a prognostic biomarker.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
  2. Holschneider CH, Berek JS: Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3–10.
  3. Mita AC, Mita MM, Nawrocki ST, Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000–5005.
  4. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC: Activation of NF-ĸb and upregulation of intracellular anti-apoptotic proteins via the IGF-1/AKT signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673–5683.
  5. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC: An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004;279:34087–34090.
  6. Song Z, Yao X, Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003;278:23130–23140.
  7. Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM: Survivin: a promising tumor biomarker. Cancer Lett 2007;249:49–60.
  8. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005;116:100–104.
  9. Wu YK, Chen KT, Kuo YB, Huang YS, Chan EC: Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. Cancer Lett 2009;273:331–335.
  10. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, Topuz E: Serum BCL-2 and survivin levels in melanoma. Melanoma Res 2004;14:543–546.
  11. Guney N, Soydine HO, Derin D, Camlica H, Duranyildiz D, Yasasever V, Topuz E: Serum and urine survivin levels in breast cancer. Med Oncol 2006;23:335–340.
  12. Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, Yasasever V, Topuz E: Serum levels of apoptosis biomarkers, survivin and TNF-α in nonsmall cell lung cancer. Lung Cancer 2008;59:240–245.
  13. Goksel G, Taneli F, Uslu R, Ulman C, Dinc G, Coskun T, Kandiloglu AR: Serum HER-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer. J Int Med Res 2007;35:165–172.
  14. Andersen MH, Svane IM, Becker JC, Straten PT: The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007;13:5991–5994.
  15. Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M: Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. Oncol Rep 2006;15:773–778.
  16. Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS, Frezza EE: Survivin expression in ovarian cancer. Exp Oncol 2007;29:121–125.
  17. Chang JT, Wong FH, Liao CT, Chen IH, Wang HM, Cheng AJ: Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 2004;50:1261–1264.
  18. Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, Acevedo-Martinez S, De Leon M, Langridge WH, Wall NR: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer 2009;100:1073–1086.
  19. Altieri DC: New wirings in the survivin networks. Oncogene 2008;27:6276–6284.
  20. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61–70.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50